We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Troponin Complexes Explored in Acute MI Patients

By LabMedica International staff writers
Posted on 22 Aug 2019
Acute myocardial infarction is the medical name for a heart attack. More...
A heart attack is a life-threatening condition that occurs when blood flow to the heart muscle is abruptly cut off, causing tissue damage. This is usually the result of a blockage in one or more of the coronary arteries.

The troponin complex is a component of the contractile apparatus of striated and cardiac muscles. The measurement of cardiac isoforms of troponin I (cTnI) and troponin T (cTnT) is widely used for the diagnosis of acute myocardial infarction (AMI). In the heart, these cardiac troponin complexes are composed of these specific cardiac isoforms and a cardiac/slow skeletal isoform of troponin C (TnC). On acute myocardial infarction (AMI), troponins are released from necrotic tissue into the bloodstream.

A team of scientists linked up with those at the commercial company HyTest Ltd (Turku, Finland) collected serial blood samples from 38 patients (148 samples in total) were collected between 2 and 33 hours following the onset of chest pain. Blood was withdrawn by means of venipuncture into 10-mL vacutainer blood-collection tubes coated with Li-heparin. Tubes were inverted several times and centrifuged for 20 minutes at 1500g. The resulting plasma was decanted and stored at −70 °C in 5-mL polypropylene tubes. Heparin plasma samples from 11 apparently healthy individuals, 25 to 40 years of age, were pooled and stored at −70 °C.

The team measured cTnI and cTnT concentrations in all Li-heparin plasma samples were measured by in-house immunofluorescence assays (FIA) utilizing TnI19C7-TnI560 and TnT329-TnT406 assays, respectively. All samples were analyzed by a 2-step FIA using Eu-labeled monoclonal antibodies (mAbs). They also conducted “mixed sandwich assays” in which capture and detection mAbs were specific to different components of troponin complexes. The gel filtration (GF) studies were performed using an AKTA pure chromatography system on a HiLoad Superdex 200 PG 16/60 column. Cardiac troponins and their fragments were analyzed using 15% to 22.5% gradient SDS-PAGE according to Laemmli under reducing conditions using a Hoefer SE280 electrophoresis unit.

Plasma samples from patients with AMI contained the following troponin complexes: (a) a cTnI-cTnT-TnC complex (ITC) composed of full-size cTnT of 37 kDa or its 29-kDa fragment and full-size cTnI of 29 kDa or its 27-kDa fragments; (b) ITC with lower molecular weight (LMW-ITC) in which cTnT was truncated to the 14-kDa C-terminal fragments; and (c) a binary cTnI-cTnC complex composed of truncated cTnI of approximately 14 kDa.

During the progression of the disease, the amount of ITC in AMI samples decreased, whereas the amounts of LMW-ITC and short 16- to 20-kDa cTnT central fragments increased. Almost all full-size cTnT and a 29-kDa cTnT fragment in AMI plasma samples were the components of ITC. No free full-size cTnT was found in AMI plasma samples. Only 16- to 27-kDa central fragments of cTnT were present in a free form in patient blood.

The authors concluded that a ternary troponin complex exists in two forms in the blood of patients with AMI: full-size ITC and LMW-ITC. The binary cTnI-cTnC complex and free cTnT fragments are also present in patient blood. The study was published on the July 2019 issue of the journal Clinical Chemistry.

Related Links:
HyTest


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.